NanoViricides, Inc. to Participate in D. Boral Capital Inaugural Global Conference on May 14, 2025
NanoViricides, Inc., a clinical-stage company developing antivirals, to join D. Boral Capital Global Conference. Learn about lead drug candidate NV-387 for COVID-19 and respiratory infections.
This news matters as it highlights NanoViricides' active involvement in developing innovative antiviral therapies, particularly amid the ongoing COVID-19 pandemic. Investors and stakeholders can gain insights into the company's advancements and potential impact on the healthcare industry.
